Citi maintains 'Buy' rating on POZEN Inc (Nasdaq: POZN), price target $15.

Citi analyst says, "Treximet, for migraine, PDUFA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE